Decentralized scientific trial firm Curebase raised $40 million in a Series B spherical led by Industry Ventures.
Acrew Capital, World Innovation Lab, Positive Sum, Gaingels, GGV Capital, Bold Capital and Xfund participated within the funding, which additionally included a strategic funding from pharma large Gilead Sciences. The spherical brings Curebase’s complete increase to $59 million.
WHAT IT DOES
Curebase gives software program and operations assist for managing decentralized scientific trials. That contains an app for sufferers to allow them to discover and enroll in trials, signal consent kinds, entry telemedicine and schedule residence visits. The firm additionally gives a site-facing platform to help with recruitment, prescreening potential members and managing their scientific trials.
Outside of software program, Curebase staffers like principal investigators, analysis coordinators and undertaking managers may also help execute scientific trials by discovering potential websites, coaching and establishing software program, and recruiting and retaining sufferers.
“Your traditional clinical trial takes place at a big hospital, it’s limited to on-site participation. And that can lead to slow recruitment of patients, loss of diversity and a less satisfying patient experience, which ultimately brings drugs and devices to market more slowly,” Curebase founder and CEO Tom Lemberg advised MobiHealthInformation.
“So we take the trial to the patient. And our vision is really to enable any patient to be in a clinical trial, wherever they live, at home and with their own doctor in their own community.”
WHAT IT’S FOR
The startup plans to make use of the capital to put money into its platform, together with by rising their design workforce to enhance the consumer expertise for sufferers. Curebase will even rent scientific providers staff and develop its attain in Europe.
“We’re also positioning for more complex types of trials. And we’re really investing heavily in some of the things that our pharma and biotech customers are looking for,” Lemberg mentioned.
“So we’re really investing in our electronic data capture systems, direct data capture systems, remote monitoring, remote risk-based monitoring, [and] data management, so that we can go beyond just that virtual experience and do enterprise-grade data management for those more complex pharmaceutical and biotech studies.”
The marketplace for decentralized scientific trial expertise grew throughout the COVID-19 pandemic, as telehealth and digital care expanded. Other firms within the area embody THREAD, which earlier this month introduced it had acquired trial recruitment platform CureClick; Reify Health, which just lately raised $220 million in Series D funding; and Medable, which landed greater than $300 million in October final yr.
“I think that before COVID there was already a goal to do what we wanted to do. The idea that clinical trials should be more patient-centric, they should reach patients at home in their communities, they should be faster, they should be more diverse, and that should be done via technology. I think that’s existed for a long time,” Lemberg mentioned.
“But of course, there’s risk aversion, and it makes it hard to implement those things. I think COVID really changed that by making it worth taking that chance.”